← All Ascendis Pharma A/s filings

Ascendis Pharma A/s 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
ASND
Ascendis Pharma A/s
20-F: Ascendis Pharma Reports Strong Revenue Growth, Expands Portfolio
Ascendis Pharma A/S reported significant revenue growth in 2025, driven by strong global sales of YORVIPATH and SKYTROFA, while advancing its rare disease and oncology pipelines.
NASDAQ
ASND
Ascendis Pharma A/s
20-F: Ascendis Pharma Reports Full Year 2024 Results, Highlights Progress in Endocrinology and Oncology
Ascendis Pharma's 20-F filing summarizes the company's financial performance, key developments, and future outlook, emphasizing its focus on endocrinology, rare diseases, and oncology.
NASDAQ
ASND
Ascendis Pharma A/s
20-F: Ascendis Pharma Inks Revenue Participation Deal with Royalty Pharma for $150 Million
Ascendis Pharma secures $150 million through a revenue participation agreement with Royalty Pharma, focusing on U.S. sales of SKYTROFA.